{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T06:32:30Z","timestamp":1793514750202,"version":"4.5.0"},"reference-count":30,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"unspecified","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Orion Pharma"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2024,6,28]]},"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Both physicians and patients are increasingly aware of the environmental impacts of medication. The shift of treatment paradigm towards MART-treatment (Maintenance and Reliever Therapy) in asthma affects the treatment-related emissions. The carbon footprint of inhaled medication is also tied to the type of the device used. Today the most commonly used propellant-containing pressurised metered-dose inhalers (pMDIs) have a carbon footprint typically 20\u201340-fold higher than propellant-free dry powder inhalers (DPIs) and soft mist inhalers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analysed the carbon footprint of inhaled medications in Europe using published life cycle analyses of marketed inhalers and comprehensive 2020 European sales data. In addition, we give an estimate on treatment-related emissions of different treatment regimens on Global Initiative for Asthma (GINA) step 2.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There is potential to reduce the carbon footprint of inhaled medications by 85% if DPIs are preferred over pMDIs. Emissions from pMDIs in the EU were estimated to be 4.0 megatons of carbon dioxide equivalent (MT CO<jats:sub>2<\/jats:sub>e) and this could be reduced to 0.6 MT CO<jats:sub>2<\/jats:sub>e if DPIs were used instead. In the treatment of moderate asthma with DPI, an as-needed combination of inhaled corticosteroid and long-acting beta-agonist in a single inhaler had a substantially lower annual carbon footprint (0.8\u2009kg CO<jats:sub>2<\/jats:sub>e) than the more traditional maintenance therapy with an inhaled corticosteroid alone with as-needed short-acting beta-agonist (2.9\u2009kg CO<jats:sub>2<\/jats:sub>e).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>There has been an urgent call for healthcare to reduce its carbon footprint for appropriate patients with asthma and chronic obstructive pulmonary disease (COPD), changing to non-propellant inhalers can reduce the carbon footprint of their treatment by almost 20-fold.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjresp-2023-001782","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T04:00:16Z","timestamp":1725249616000},"page":"e001782","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Thoughtful prescription of inhaled medication has the potential to reduce inhaler-related greenhouse gas emissions by 85%"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9833-6965","authenticated-orcid":false,"given":"Ville","family":"Vartiainen","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine, Helsinki University Hospital Heart and Lung Center, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley A","family":"Woodcock","sequence":"additional","affiliation":[{"name":"University NHS Foundation Trust, UK, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1808-3663","authenticated-orcid":false,"given":"Alex","family":"Wilkinson","sequence":"additional","affiliation":[{"name":"Respiratory Department, East and North Hertfordshire NHS Trust, Stevenage, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5093-6980","authenticated-orcid":false,"given":"Christer","family":"Janson","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unnur","family":"Bj\u00f6rnsd\u00f3ttir","sequence":"additional","affiliation":[{"name":"Department of Allergy and Pulmonary Medicine, University Hospital Iceland, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tari","family":"Haahtela","sequence":"additional","affiliation":[{"name":"Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauri","family":"Lehtim\u00e4ki","sequence":"additional","affiliation":[{"name":"Allergy Centre, Tampere University Hospital, Tampere, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,9,1]]},"reference":[{"key":"2025083110034402000_11.1.e001782.1","unstructured":"WHO . Climate change and health. 2018. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/climate-change-and-health [Accessed 13 May 2021]."},{"key":"2025083110034402000_11.1.e001782.2","unstructured":"Benedick . Montreal protocol on substances that deplete the ozone layer medical and chemical technical options committee. 2018 assessment report. 2018."},{"key":"2025083110034402000_11.1.e001782.3","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.jaip.2020.09.026","article-title":"Peak Inspiratory Flow Measured at Different Inhaler Resistances in Patients with Asthma","volume":"9","author":"Haughney","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025083110034402000_11.1.e001782.4","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2147\/COPD.S291554","article-title":"Peak Inspiratory Flow Rate in COPD: An Analysis of Clinical Trial and Real-World Data","volume":"16","author":"Anderson","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025083110034402000_11.1.e001782.5","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-020-01246-z","article-title":"Inhaler devices in asthma and COPD patients - a prospective cross-sectional study on inhaler preferences and error rates","volume":"20","author":"Schreiber","year":"2020","journal-title":"BMC Pulm Med"},{"key":"2025083110034402000_11.1.e001782.6","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2019-213744"},{"key":"2025083110034402000_11.1.e001782.7","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-028763","article-title":"Costs of switching to low global warming potential inhalers. An economic and carbon footprint analysis of NHS prescription data in England","volume":"9","author":"Wilkinson","year":"2019","journal-title":"BMJ Open"},{"key":"2025083110034402000_11.1.e001782.8","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jaci.2016.12.001","article-title":"The Finnish experience to save asthma costs by improving care in 1987-2013","volume":"139","author":"Haahtela","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2025083110034402000_11.1.e001782.9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1065\/lca2006.04.019","article-title":"The Role of SETAC in the Development of LCA","volume":"11","author":"Kl\u00f6pffer","year":"2006","journal-title":"Int J Life Cycle Assess"},{"key":"2025083110034402000_11.1.e001782.10","unstructured":"IPCC AR6 WGI chapter 7 supplementary material. Available: https:\/\/www.ipcc.ch\/report\/ar6\/wg1\/downloads\/report\/IPCC_AR6_WGI_Chapter_07_Supplementary_Material.pdf [Accessed 10 Apr 2022]."},{"key":"2025083110034402000_11.1.e001782.11","unstructured":"Global Initiative for Asthma . Global strategy for asthma management and prevention. 2021."},{"key":"2025083110034402000_11.1.e001782.12","unstructured":"Global Initiative for Chronic Obstructive Lung Disease . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2020."},{"key":"2025083110034402000_11.1.e001782.13","unstructured":"Eurostat . Population change - demographic balance and crude rates at national level. Available: https:\/\/ec.europa.eu\/eurostat\/databrowser\/view\/demo_gind\/default\/table?lang=en [Accessed 02 Aug 2021]."},{"key":"2025083110034402000_11.1.e001782.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715275"},{"key":"2025083110034402000_11.1.e001782.15","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01233-0"},{"key":"2025083110034402000_11.1.e001782.16","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2147\/PPA.S242215","article-title":"The Impact of A Forced Non-Medical Switch of Inhaled Respiratory Medication Among Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Patient Survey on Experience with Switch, Therapy Satisfaction, and Disease Control","volume":"14","author":"Gilbert","year":"2020","journal-title":"Pat Prefer Adherence"},{"key":"2025083110034402000_11.1.e001782.17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s41030-019-0097-7","article-title":"Effectiveness and Patient Satisfaction with Budesonide\/Formoterol Easyhaler\u00ae Among Patients with Asthma or COPD Switching from Previous Treatment: a Real-World Study of Patient-Reported Outcomes","volume":"5","author":"G\u00e1lffy","year":"2019","journal-title":"Pulm Ther"},{"key":"2025083110034402000_11.1.e001782.18","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2018-212957"},{"key":"2025083110034402000_11.1.e001782.19","unstructured":"United States Environmental Protection Agency . Greenhouse gas emissions from a typical passenger vehicle. 2018."},{"key":"2025083110034402000_11.1.e001782.20","doi-asserted-by":"crossref","first-page":"074024","DOI":"10.1088\/1748-9326\/aa7541","article-title":"The climate mitigation gap: education and government recommendations miss the most effective individual actions","volume":"12","author":"Wynes","year":"2017","journal-title":"Environ Res Lett"},{"key":"2025083110034402000_11.1.e001782.21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2020-000571","article-title":"Environmental impact of inhalers for respiratory diseases: decreasing the carbon footprint while preserving patient-tailored treatment","volume":"7","author":"Panigone","year":"2020","journal-title":"BMJ Open Respir Res"},{"key":"2025083110034402000_11.1.e001782.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclepro.2019.117733"},{"key":"2025083110034402000_11.1.e001782.23","unstructured":"U.S. Environmental Protection Agency . Market characterization of the U.S. metered dose inhaler industry. 2021. Available: https:\/\/www.epa.gov\/sites\/default\/files\/2021-03\/documents\/epa-hq-oar-2021-0044-0002_attachment_1-mdis.pdf?VersionId=EonCVwZG6UXYmpe9hmej95NIM0B2zUlr"},{"key":"2025083110034402000_11.1.e001782.24","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2021-001071","article-title":"Reducing carbon footprint of inhalers: analysis of climate and clinical implications of different scenarios in five European countries","volume":"8","author":"Pernigotti","year":"2021","journal-title":"BMJ Open Respir Res"},{"key":"2025083110034402000_11.1.e001782.25","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2022-BTSabstracts.66"},{"key":"2025083110034402000_11.1.e001782.26","unstructured":"Masson-Delmotte V , Zhai P , P\u00f6rtner H-O , et al ., eds. Global Warming of 1.5\u00b0C. 2018."},{"key":"2025083110034402000_11.1.e001782.27","doi-asserted-by":"crossref","first-page":"e1493","DOI":"10.1016\/S2214-109X(21)00398-3","article-title":"Call for emergency action to limit global temperature increases, restore biodiversity, and protect health","volume":"9","author":"Atwoli","year":"2021","journal-title":"Lancet Glob Health"},{"key":"2025083110034402000_11.1.e001782.28","unstructured":"Carbon Footprint Ltd . Product footprint executive summary for orion pharma. 2021. Available: https:\/\/www.orion.fi\/globalassets\/documents\/orion-group\/sustainability\/2021_04-orion-pharma-product-footprint-lca-executive-summary-v1.0.pdf"},{"key":"2025083110034402000_11.1.e001782.29","unstructured":"Carbon Trust Ltd . Product carbon footprint certification summary report. 2014."},{"key":"2025083110034402000_11.1.e001782.30","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1007\/s12325-019-01028-y","article-title":"Inhaler Compared with Pressurised Metered-Dose Inhalers","volume":"36","author":"H\u00e4nsel","year":"2019","journal-title":"Adv Ther"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2023-001782","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T17:03:55Z","timestamp":1756659835000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2023-001782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,9,1]]},"published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1136\/bmjresp-2023-001782"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2023-001782","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]}}}